Actinium Pharmaceuticals Inc

Actinium Pharmaceuticals, Inc. develops antibody radiation conjugates and other targeted radiotherapies to improve outcomes for patients who have failed existing oncology therapies. Its pipeline includes Actimab-A, a CD33-targeting radiotherapeutic in a Phase 2/3 trial for relapsed/refractory AML; Iomab-ACT, aimed at improving access to and outcomes with cellular therapies such as CAR-T and gene therapies for non-malignant hematologic disorders like sickle cell disease; and ATNM-400, an antibody radioconjugate that delivers the alpha-emitter Ac-225 to prostate cancer cells. Iomab-B is an induction and conditioning agent used prior to bone marrow transplant in patients with relapsed and refractory acute myeloid leukemia. The company also collaborates with the National Cancer Institute under a cooperative research and development agreement for Actimab-A in AML and other myeloid malignancies, and its R&D activities primarily focus on advancing preclinical programs for solid tumor indications. It is based in New York, New York.